HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MABWELL-B

20.580

-0.020-0.10%

Volume:206.80K

Turnover:4.22M

Market Cap:9.20B

PE:-8.47

High:20.580

Open:21.000

Low:20.300

Close:20.600

52wk High:31.460

52wk Low:19.860

Shares:447.00M

HK Float Shares:47.13M

Volume Ratio:0.88

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.430

ROE:-91.76%

ROA:-10.61%

PB:9.02

PE(LYR):-8.47

PS:9.01

Loading ...

Overview Company News Filings

MABWELL-B to Present Latest Clinical Data for 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

MABWELL-B Announces Change in Authorized Representative

Mabwell appoints Executive Director Hua Jun as new authorised representative

Bulletin Express

Mabwell Announces Updated Board Composition and Committee Appointments

Bulletin Express

MABWELL-B Appoints Dr. Gui Xun as Employee Representative Director

Mabwell Bioscience Clears All Agenda Items at 2026 Third EGM; Approves EY as Auditor and New H-Share Issuance Mandate

Bulletin Express

MABWELL-B Shares Surge on Strategic Collaboration in Ophthalmology

MABWELL-B Shares Surge Over 6% Following FDA Clearance for Key Cancer Drug Trial

Mabwell Receives FDA Clearance for Clinical Trial of Investigational Drug 6MW5311

Flagship Asset Demonstrates Combination Potential, <b>MABWELL-B</b> (02493) Sees Commercialization Certainty Gradually Materializing

MABWELL-B Shares Surge Over 7% Following Clinical Trial Approval for Novel Inflammatory Bowel Disease Antibody

MABWELL-B Shares Surge Over 7% Against Market Trend Following Clinical Trial Approval

Mabwell Maintains Stable Share Base in May 2026; Confirms Public-Float Compliance

Bulletin Express

Mabwell gains NMPA green light for first-in-class antibody 9MW5211; IBD trial cleared in China and the U.S., MS filing accepted

Bulletin Express

Mabwell Receives Chinese Regulatory Nod for Clinical Trial of Investigational Drug 9MW5211

MABWELL-B Proposes New Executive Director Appointments

Mabwell Bioscience Releases Revised Articles of Association Detailing Governance, Capital Structure and Dividend Policy

Bulletin Express

MABWELL-B Shares Surge Over 6% on Upcoming ASCO Data Presentation for Key Drug Candidate

Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting

Mabwell Gets Chinese Regulatory Nod to Expand Indication of Denosumab

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/02493/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02493","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"MABWELL-B","latestPrice":20.58,"timestamp":1789027722187,"preClose":20.6,"halted":0,"volume":206800,"delay":0,"changeRate":-0.0009708737864079187,"floatShares":47130200,"shares":447000000,"eps":-2.43,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"09-10 16:08:42","open":21,"high":20.58,"low":20.3,"amount":4219292,"amplitude":0.013592,"askPrice":20.58,"askSize":200,"bidPrice":20.36,"bidSize":1800,"shortable":0,"etf":0,"ttmEps":-2.422,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":20.6,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.875085,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"Mabwell(Shanghai)Bioscience Co.,Ltd.","latestPrice":25.6,"timestamp":1789023600000,"preClose":26.02,"halted":0,"volume":5291800,"delay":0,"premium":"-31.18"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","floatShares":47130200,"roa":"-10.61%","roe":"-91.76%","lyrEps":-2.43,"volumeRatio":0.875085,"shares":447000000,"dividePrice":0,"high":20.58,"amplitude":0.013592,"preClose":20.6,"low":20.3,"week52Low":19.86,"pbRate":"9.02","psRate":"9.01","week52High":31.46,"institutionHeld":0,"latestPrice":20.58,"committee":0.8,"eps":-2.43,"divideRate":0,"volume":206800,"delay":0,"ttmEps":-2.422,"open":21,"prevYearClose":27.64,"prevWeekClose":20.76,"prevMonthClose":20.7,"prevQuarterClose":23.32,"fiveDayClose":20.84,"twentyDayClose":23.3,"sixtyDayClose":25.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02493\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2026-08-31","symbol":"02493","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1788105600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02493\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02493\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1783699200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02493\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02493","date":"2026-09-09","current":-8.49711,"percent":1,"low":-17.302507,"twenty":-15.659552,"median":-14.431979,"eighty":-12.99766,"high":-11.915593,"avg":-14.409238,"sd":1.378269,"marketCap":13085627584.26},"quantilePoints":[{"date":"2026-04-24","current":-15.289641,"twenty":-16.199622,"median":-15.659552,"eighty":-15.437605,"marketCap":17000217748.15},{"date":"2026-04-30","current":-16.640195,"twenty":-16.379645,"median":-15.593679,"eighty":-15.250239,"marketCap":17562577595.07},{"date":"2026-05-08","current":-16.416983,"twenty":-16.631559,"median":-16.471868,"eighty":-15.350449,"marketCap":17380742435.69},{"date":"2026-05-15","current":-16.009725,"twenty":-16.685787,"median":-16.416983,"eighty":-15.606854,"marketCap":16994157190.87},{"date":"2026-05-22","current":-15.517615,"twenty":-16.631559,"median":-16.0746,"eighty":-15.529829,"marketCap":16434142933.1},{"date":"2026-05-29","current":-14.179755,"twenty":-16.597014,"median":-15.628209,"eighty":-15.240388,"marketCap":15069483633.31},{"date":"2026-06-05","current":-12.517432,"twenty":-16.559668,"median":-15.581594,"eighty":-14.26556,"marketCap":13322161865.15},{"date":"2026-06-12","current":-13.472006,"twenty":-16.526753,"median":-15.469041,"eighty":-13.356302,"marketCap":14328406594.37},{"date":"2026-06-18","current":-12.99766,"twenty":-16.438937,"median":-15.265014,"eighty":-12.92448,"marketCap":13857073336},{"date":"2026-06-26","current":-12.199681,"twenty":-16.378066,"median":-14.95714,"eighty":-12.901569,"marketCap":12942815528.08},{"date":"2026-07-03","current":-14.979824,"twenty":-16.23102,"median":-14.955208,"eighty":-12.918972,"marketCap":15904197681.19},{"date":"2026-07-10","current":-14.849801,"twenty":-16.061625,"median":-14.902504,"eighty":-12.970767,"marketCap":15746801597.92},{"date":"2026-07-17","current":-14.420221,"twenty":-16.08484,"median":-14.955208,"eighty":-13.013901,"marketCap":15345691723.29},{"date":"2026-07-24","current":-14.443737,"twenty":-16.025201,"median":-14.968482,"eighty":-13.071825,"marketCap":15374169818.76},{"date":"2026-07-31","current":-13.354051,"twenty":-15.926439,"median":-14.902504,"eighty":-13.105062,"marketCap":14241292067.7},{"date":"2026-08-07","current":-14.221458,"twenty":-15.744727,"median":-14.562278,"eighty":-13.056126,"marketCap":15195777985.44},{"date":"2026-08-14","current":-15.770582,"twenty":-15.789139,"median":-14.806347,"eighty":-13.105062,"marketCap":16872365889.11},{"date":"2026-08-21","current":-14.469039,"twenty":-15.760286,"median":-14.849801,"eighty":-13.131915,"marketCap":15514103639.81},{"date":"2026-08-28","current":-13.731399,"twenty":-15.716499,"median":-14.541981,"eighty":-13.197968,"marketCap":14726523718},{"date":"2026-09-04","current":-12.516523,"twenty":-15.668212,"median":-14.452874,"eighty":-13.105062,"marketCap":13723599618.54},{"date":"2026-09-09","current":-11.915593,"twenty":-15.659552,"median":-14.431979,"eighty":-12.99766,"marketCap":13085627584.26}],"updateTime":1789035607847},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02493\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1148473514","title":"MABWELL-B to Present Latest Clinical Data for 9MW2821 at 2026 ESMO Gynaecological Cancers Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1148473514","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148473514?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:20","pubTimestamp":1781792456,"startTime":"0","endTime":"0","summary":"MABWELL-B (ASX: 02493) has announced that it will present the latest clinical data for its innovative Nectin-4-targeting ADC drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 European Society...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151129021","title":"MABWELL-B Announces Change in Authorized Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1151129021","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151129021?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:06","pubTimestamp":1781791576,"startTime":"0","endTime":"0","summary":"MABWELL-B (ASX: 02493) has issued an announcement regarding a change in its authorized representative.Effective from June 18, 2026, Mr. Hu Huiguo will step down from his role as the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107429031","title":"Mabwell appoints Executive Director Hua Jun as new authorised representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1107429031","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107429031?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:05","pubTimestamp":1781791501,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. announced that, effective 18 June 2026, Executive Director Mr. Hua Jun has been appointed as an authorised representative of the company under Rule 3.05 of the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149771039","title":"Mabwell Announces Updated Board Composition and Committee Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=1149771039","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149771039?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:04","pubTimestamp":1781791499,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. released an updated roster of its Board of Directors and committee assignments, effective 18 June 2026. The Board now comprises nine directors: • Executive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145752256","title":"MABWELL-B Appoints Dr. Gui Xun as Employee Representative Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1145752256","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145752256?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:52","pubTimestamp":1781790735,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (MABWELL-B (02493)) has announced a new board appointment.According to a company filing, Dr. Gui Xun was elected as an employee representative director to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122315847","title":"Mabwell Bioscience Clears All Agenda Items at 2026 Third EGM; Approves EY as Auditor and New H-Share Issuance Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1122315847","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122315847?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:44","pubTimestamp":1781790278,"startTime":"0","endTime":"0","summary":"The 2026 third extraordinary general meeting (EGM) of Mabwell (Shanghai) Bioscience Co., Ltd. convened on 18 June 2026 in Shanghai, with all directors present in person or electronically. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197090310","title":"MABWELL-B Shares Surge on Strategic Collaboration in Ophthalmology","url":"https://stock-news.laohu8.com/highlight/detail?id=1197090310","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197090310?lang=en_us&edition=fundamental","pubTime":"2026-06-17 11:44","pubTimestamp":1781667890,"startTime":"0","endTime":"0","summary":"Shares of MABWELL-B (ASX: 02493) have risen by more than 3%. At the time of writing, the stock is up 2.72% to HK$26.48, with a turnover of HK$6.48 million.The increase follows news of a strategic...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","02493","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189033943","title":"MABWELL-B Shares Surge Over 6% Following FDA Clearance for Key Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1189033943","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189033943?lang=en_us&edition=fundamental","pubTime":"2026-06-15 11:54","pubTimestamp":1781495663,"startTime":"0","endTime":"0","summary":"Shares of MABWELL-B (02493) rose more than 6% in morning trading. At the time of writing, the stock was up 6.22% to HK$26.66, with a turnover of HK$12.56 million.The price movement follows a company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","VXUS","BK4588","02493","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180918672","title":"Mabwell Receives FDA Clearance for Clinical Trial of Investigational Drug 6MW5311","url":"https://stock-news.laohu8.com/highlight/detail?id=1180918672","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180918672?lang=en_us&edition=fundamental","pubTime":"2026-06-12 16:34","pubTimestamp":1781253263,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a Clinical Study May Proceed notice from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK0239","02493","688062","BK4585","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173474197","title":"Flagship Asset Demonstrates Combination Potential, <b>MABWELL-B</b> (02493) Sees Commercialization Certainty Gradually Materializing","url":"https://stock-news.laohu8.com/highlight/detail?id=1173474197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173474197?lang=en_us&edition=fundamental","pubTime":"2026-06-12 16:21","pubTimestamp":1781252508,"startTime":"0","endTime":"0","summary":"As we pass the midpoint of 2026, MABWELL-B (02493) is positioned at the starting line of a new round of value reassessment. With the release of multiple significant clinical datasets for its core...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179539839","title":"MABWELL-B Shares Surge Over 7% Following Clinical Trial Approval for Novel Inflammatory Bowel Disease Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1179539839","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179539839?lang=en_us&edition=fundamental","pubTime":"2026-06-11 14:43","pubTimestamp":1781160222,"startTime":"0","endTime":"0","summary":"MABWELL-B (HKEX: 02493) shares have surged more than 7% in today's trading session. At the time of writing, the stock is up 5.71%, trading at HK$25.9 with a turnover of HK$48.537 million. Key...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","BK1161","BK4588","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123729715","title":"MABWELL-B Shares Surge Over 7% Against Market Trend Following Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1123729715","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123729715?lang=en_us&edition=fundamental","pubTime":"2026-06-10 10:12","pubTimestamp":1781057543,"startTime":"0","endTime":"0","summary":"Shares of MABWELL-B (02493) have risen more than 7%, moving against the broader market trend.As of the latest update, the stock is up 6.54% to HK$23.78, with a trading volume of HK$8.6025 million.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","02493","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146597371","title":"Mabwell Maintains Stable Share Base in May 2026; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146597371","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146597371?lang=en_us&edition=fundamental","pubTime":"2026-06-05 08:03","pubTimestamp":1780617784,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (Mabwell) filed its Monthly Return for Equity Issuer for the period ended 31 May 2026, confirming that no changes occurred in either its authorised or issued...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114470341","title":"Mabwell gains NMPA green light for first-in-class antibody 9MW5211; IBD trial cleared in China and the U.S., MS filing accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1114470341","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114470341?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:24","pubTimestamp":1780579497,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. announced that China’s National Medical Products Administration has approved a clinical trial application for 9MW5211 injection in inflammatory bowel disease...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167249178","title":"Mabwell Receives Chinese Regulatory Nod for Clinical Trial of Investigational Drug 9MW5211","url":"https://stock-news.laohu8.com/highlight/detail?id=1167249178","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167249178?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:12","pubTimestamp":1780567949,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (ASX: 688062), also known as Mabwell-B (ASX: 02493), has announced that its clinical trial application for the investigational drug 9MW5211 injection has...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK0239","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168787822","title":"MABWELL-B Proposes New Executive Director Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=1168787822","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168787822?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228827,"startTime":"0","endTime":"0","summary":"MABWELL-B (02493) has announced that its second-term board of directors was elected at the company's 2022 annual general meeting on April 27, 2023. The term for this board will run from June 21,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124612640","title":"Mabwell Bioscience Releases Revised Articles of Association Detailing Governance, Capital Structure and Dividend Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=1124612640","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124612640?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:44","pubTimestamp":1780065852,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell Bioscience”) has published an updated Articles of Association (effective May 2026), outlining key corporate governance mechanisms, share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173177905","title":"MABWELL-B Shares Surge Over 6% on Upcoming ASCO Data Presentation for Key Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1173177905","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173177905?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:52","pubTimestamp":1779414744,"startTime":"0","endTime":"0","summary":"MABWELL-B (02493) rose more than 6%. At the time of writing, the stock was up 5.22% to HKD 25.8, with a turnover of HKD 7.1328 million. The company announced that it will present the latest clinical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02493","BK1161","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187250283","title":"Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1187250283","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187250283?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:21","pubTimestamp":1779355318,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02493","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637053928","title":"Mabwell Gets Chinese Regulatory Nod to Expand Indication of Denosumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2637053928","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637053928?lang=en_us&edition=fundamental","pubTime":"2026-05-21 11:16","pubTimestamp":1779333367,"startTime":"0","endTime":"0","summary":"Mabwell  Bioscience  said Chinese regulators expanded denosumab's approval to include new indications, according to a Wednesday filing with the Hong Kong bourse.The firm's Hong Kong shares gained nearly 4% in morning trade Thursday.Denosumab, also known as maiweijian and 9MW0321, will now be available to treat bone metastases from solid tumors and to delay or reduce the risk of skeletal-related events in patients with multiple myeloma.The medicine, a biosimilar version of Xgeva, was previously approved in China to treat giant cell tumor of the bone.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02493","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":71,"code":"91000000","status":"200"}]}}